Overview

• A phase III clinical trial of 438 participants demonstrated that ubrogepant can reduce prodromal symptoms such as fatigue, photophobia, and neck pain before a migraine headache begins.
• The trial showed modest effect sizes, with symptom improvements up to 15 percentage points higher than placebo, such as a 27% reduction in fatigue compared to 17% with placebo.
• Participants took ubrogepant or a placebo at the onset of prodromal symptoms, reporting symptom relief within one to three hours post-treatment.
• The findings support a brain-origin model for migraines, reinforcing the role of central nervous system pathways rather than peripheral vascular causes.
• Researchers highlight the clinical relevance of treating prodromal symptoms alone, though further studies are needed to explore effects on aura and postdrome phases.